Share this article on:

ACSM4 Polymorphisms Are Associated With Rapid AIDS Progression in HIV-Infected Patients

Guzmán-Fulgencio, María PhD*; Jiménez, José L. PhD; Jiménez-Sousa, María A. PhD*; Bellón, José M. PhD; García-Álvarez, Mónica PhD*; Soriano, Vicente MD, PhD§; Gijón-Vidaurreta, Paloma MD, PhD; Bernal-Morell, Enrique MD, PhD; Viciana, Pompeyo MD, PhD#; Muñoz-Fernández, M. Ángeles MD, PhD**,††,‡‡; Resino, Salvador PhD*

JAIDS Journal of Acquired Immune Deficiency Syndromes: January 1st, 2014 - Volume 65 - Issue 1 - p 27–32
doi: 10.1097/QAI.0b013e3182a990e2
Brief Report: Basic and Translational Science

Abstract: Our aim was to explore the association among ACSM4 and PECI polymorphisms and AIDS progression in 454 HIV-infected patients never treated with antiretroviral drugs (146 long-term nonprogressors, 228 moderate progressors, and 80 rapid progressors). For ACSM4 polymorphisms, rs7137120 AA/AG and rs7961991 CC/CT genotypes had higher odds of having a rapid AIDS progression [odds ratio (OR) = 3.21; 95% of confidence interval (95% CI) = 1.26 to 8.16; P = 0.014 and OR = 3.60; 95% CI = 1.38 to 9.36; P = 0.009, respectively]. Additionally, the ACSM4 haplotype integrated for both rs7961991 A and rs7137120 C alleles had higher odds of having a rapid AIDS progression (OR = 2.85; 95% CI = 1.28 to 6.25; P = 0.010). For PECI polymorphisms, no significant associations were found. In conclusion, ACSM4 polymorphisms might play a significant role in AIDS progression.

Supplemental Digital Content is Available in the Text.

*Unidad de Coinfección HIV/Hepatitis, Centro Nacional de Microbiología, Hospital Carlos III, Madrid, Spain;

Plataforma de Laboratorio, Hospital General Universitario “Gregorio Marañón,” Madrid, Spain;

Fundación para la Investigación Biomédica, Hospital General Universitario “Gregorio Marañón,” Madrid, Spain;

§Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Spain;

Servicio Microbiología, Hospital General Universitario Gregorio Marañon, Madrid, Spain;

Servicio de Enfermedades Infecciosas, Hospital General Universitario Reina Sofia, Madrid, Spain;

#Servicio de Enfermedades Infecciosas, Hospital Virgen del Rocío, Seville, Spain;

**Laboratorio InmunoBiología Molecular, Hospital General Universitario Gregorio Marañón, Madrid, Spain;

††Instituto de Investigación Sanitaria del Gregorio Marañón, Madrid, Spain; and

‡‡Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain.

Correspondence to: Salvador Resino, PhD, Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), Carretera Majadahonda-Pozuelo, Km 2.2, 28220 Majadahonda, Madrid, Spain (e-mail:

Supported by grants given by Fondo de Investigacion de Sanidad en España (Spanish Health Founds for Research) (grant numbers: PI11/00245, PI11-00888, PS09/02029, and PS09/02669), Red Española de Investigación en SIDA (AIDS Research Network) (grant numbers: RD12/0017/0024, RD06/0006/0035, RD12/0017/0037, and RD09/0076/00103), “Fundación para la Investigación y la Prevención del Sida en España” (300509), Comunidad de Madrid (grant numbers: S-2010/BMD-2351 and S-2010/BMD-2332), PENTA, Cost action TD0802, and the “Programa de Investigacion de la Consejeria de Sanidad de la Comunidad de Madrid” to J.L.J. M.G.-F., M.G.-A., and M.A.J.-S. are supported by “Instituto de Salud Carlos III” (grant numbers: CM09/00031, CD12/00442, and CM10/00105, respectively).

The authors have no conflicts of interest to disclose.

V.S., P.G.-V., and E.B.-M.: On behalf of CoRIS and the HIV HGM Biobank integrated in the Spanish AIDS Research Network. P.V.: On behalf of LTNPs Cohort integrated in the Spanish AIDS Research Network.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (

Received June 10, 2013

Accepted August 13, 2013

© 2014 by Lippincott Williams & Wilkins